Monitoring blood for early signs of liver cancer recurrence after treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of a circulating tumor DNA (ctDNA) monitoring model in predicting the recurrence of hepatocellular carcinoma after curative treatment. It will assess whether this model can detect recurrence earlier than traditional imaging methods and explore its potential to guide adjuvant therapy. The study will involve a prospective cohort of patients who have undergone surgery for liver cancer, with a focus on analyzing their ctDNA levels over time. By establishing the predictive value of ctDNA-MRD monitoring, the study seeks to improve postoperative management of liver cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female patients aged 18-75 years;
2. Preoperative imaging examination diagnosed hepatocellular carcinoma (BCLC) stage 0 / stage A/stage B, eligible for radical surgery;
3. ECOG physical status score is 0-1;
4. Child-Pugh score is 5-6 points (Level A);
5. Not received any anti-tumor therapy;
6. Laboratory tests were at normal levels within 7 days before enrollment.

Exclusion Criteria:

1. Patient can't provide blood samples for ctDNA testing;
2. Patient with two or more types of tumors at the same time;
3. Non-primary liver lesions;
4. Pregnant or lactating women;
5. Patient with a history of other malignant tumors within the past 5 years or at the same time, except cured skin basal cell carcinoma, cervical carcinoma in situ and thyroid papillary carcinoma;
6. Patient with serious heart disease;
7. Other conditions deemed unsuitable for inclusion by the researcher.

Where it's running

• The Sixth Affiliated Hospital of South China University of Technology
  Foshan, Guangdong, China Recruiting
• Zhujiang Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting
• Affiliated Cancer Hospital and Institute of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting
• Guangdong Provincial Hospital of Traditional Chinese Medicine
  Guangzhou, Guangdong, China Recruiting
• Shunde Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting
• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Mingxin Pan — Southern Medical University, China
• Study coordinator: Mingxin Pan, Prof.
• Email: pmxwxy@sohu.com
• Phone: +8618928918216

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pre-surgery treatment with iparomlimab, tuvonralimab, and lenvatinib for liver cancer

  This trial will try a 9-week pre-surgery combination of two immune antibodies (iparomlimab and tuvonralimab) plus daily lenvatinib in people with resectable hepatocellular carcinoma who are at high risk of recurrence.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07014150

• Y-90 internal liver radiation followed by tremelimumab and durvalumab for liver cancer with portal vein thrombosis

  This will test whether Y-90 selective internal radiation (SIRT) followed by tremelimumab and durvalumab helps people with non-resectable hepatocellular carcinoma that involves the portal vein.

  Recruiting Phase 2 Center Eugene Marquis · Grenoble and 5 other locations · NCT07122089

• Combining Lenvatinib with SIRT for Advanced Liver Cancer

  This study is testing whether combining a cancer drug called lenvatinib with a type of radiation therapy can help people with advanced liver cancer that hasn't improved with other treatments.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904196

• Combination treatment for large liver cancer with portal vein involvement

  This study is testing a new combination treatment for people with large liver cancer that has spread to the portal vein to see if it works better than the standard treatment.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT06904183

• Yttrium-90 treatment for large liver cancer

  This study is testing whether a special radiation treatment using yttrium-90 can help people with large liver cancer that can’t be surgically removed feel better and live longer.

  Recruiting Phase 2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong and 1 other locations · NCT06707233

• Combination therapy for advanced liver cancer patients

  This study is testing a new combination treatment for patients with advanced liver cancer to see if it can improve their chances of survival and how well they tolerate it.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT06607107

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.